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and CZ, while PL references to all EU countries. CZ and RO employ the average
among the three lowest reference prices and BG and PL the lowest reference price.
There is a regressive margin scale in all countries. In BG, RO and PL margins are
separated for wholesalers and retailers, while in CZ they are negotiated. In CZ and
PL there are multiple insurance companies compared to BG and RO, where there is
only one. Currently RO’s reimbursement is 50% of the price for all prescription
drugs, BG and PL use 4 reimbursement levels, PL and CZ employ a complex external
and internal referencing. In CZ the reimbursement base is the cheapest medicinal
price in the group. In BG, PL and RO the reimbursement level is the cheapest price
per DDD for every INN. All countries require pharmacoeconomic evidences, but CZ
and PL employ guidelines, while BG and RO apply criteria for evaluation.
CONCLUSIONS: We deem BG and RO systems less adaptable, but clearer to follow.
CZ and PL systems show greater flexibility, due to existence of negotiation and
freedom.
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OBJECTIVES: Despite nearly 25 years of experience with recombinant human
growth hormone (GH) treatment modalities vary significantly between centres and
regions and final outcome of GH therapy varies widely . In a country like Germany,
for example, children with growth disorders are treated with Genotropin® (Pfizer
Inc, New York) in more than 150 institutions with different levels of experience.
METHODS: Data collected from more than 75,000 children with growth disorders
treated with Genotropin are followed-up worldwide in a large, pharmaco-epidemi-
ological database (KIGS, Pfizer International Growth Study). Country specific data-
sets are used to compare treatment standards and demonstrate differences be-
tween individual centres and the country as a whole. Site-specific, individualized
reports enable clinicians to anonymously benchmark the quality of care in their
treatment centre. Quality indicators (like diagnostic tests, height and height veloc-
ity, GH dose, treatment response and responsiveness, treatment duration, adverse
events, completeness of documentation) are followed and compared. RESULTS:
Structural aspects as well as process and outcome indicators differed between the
paediatric endocrinology centres, e.g. age at start of therapy, GH doses and diag-
nostic procedures. The reports allowed self-audit of clinical practice, sharing of
best practice and promote discussion of clinical decision making in paediatric
specialist care forums. CONCLUSIONS: The KIGS Quality Insight (KIGS QI) program
provides a successful approach to unmask deficits and to improve the outcome of
care. The output from the centre and country specific analysis allows identification
and follow-up of GH non-responders and assists with demonstration of standard of
care and treatment outcomes in the country to hospital managers, guidelines com-
mittees and payers. Results from KIGS can be successfully used to enable investi-
gators to compare their treatment centre with the country as a whole and to assess
changes over time.
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OBJECTIVES: To estimate costs of routine care for female urinary incontinence in
nursing care in Germany. The management of female urinary incontinence is con-
sidered as the most cumbersome task in nursing homes for the elderly. Despite the
great economic burden of incontinence, the largest cost category, routine care
costs, is poorly described, and there are limited data on cost in nursing homes
METHODS: In cooperation with a nursing home, cost of managing incontinent
patients was evaluated. Both direct patient-material and laundry costs were con-
sidered. Time required to manage an incontinent patients was also evaluated. Data
were collected on randomly selected female patients. The determination of the
cost was based on the existing prices and the usual salary of employees in nursing
homes. RESULTS: Total cost of managing an incontinent patient sums up to
€2260.06/month/patient. Cost calculation of nursing care was based on a 4 times/
day changing of diapers. This accounted in total €434.40 for the material costs
(anatomical pads, disposable gloves, hand and surface disinfectants, incontinence
bed cover, mattress protectors, pants, wound cream, protective aprons and dia-
pers). The costs for the nursing staff work amounted to €1825.66. The results are in
contrast to the publication of Schulenburg et. al who analyzed the material costs in
German Health Care System by incontinence patients. The annual costs were cal-
culated with 261 €. Personnel costs were not calculated. CONCLUSIONS: Female
urinary incontinence demands highest attention and should not be taken as symp-
tom of aging. Rather, the urinary incontinence is treatable disease, which improves
the quality of life and reduces the cost of health care. Female urinary incontinence
should be perceived as a widespread disease. Approaches would include the de-
velopment of a disease management program and the implementation in German
social act.
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OBJECTIVES:Neisseria meningitidis (Nm) is a leading cause of bacterial meningitis
and bacteremia worldwide. While infection (or carriage) is common throughout a
person’s life history, invasive meningococcal disease (IMD) is rare and is dispro-
portionately observed in infants and adolescents. Previous models that evaluated
the health and economic impact of meningococcal vaccines have not always con-
sidered key epidemiological features such as transmission mechanisms, or risk of
IMD outbreaks. Our objective was to understand which natural history assump-
tions best matched the observed time trends in disease notification data, in order to
use the most realistic model to economically evaluate new meningococcal vacci-
nation policies. METHODS: We formulated two dynamic stochastic compartmen-
tal models of Nm transmission within a population of hosts: the first assumed
transient natural immunity entailing perfect cross-protection between serogroups;
the second assumed partial (and thus imperfect) cross-immunity amongst sero-
groups. In both models, Nm infection and IMD were assumed to be distinct sto-
chastic processes and IMD was assumed to occur in a small fraction of the popu-
lation at the time infection is acquired. RESULTS: Model parameters were
calibrated to carriage data and 62-year case notification data from Canada. Sus-
tained oscillations and co-circulation of multiple serogroups are ubiquitous in the
IMD case notification data of many countries. Only the second model captured
these patterns, while the first model unrealistically predicted that one serogroup
would always disappear from the population. CONCLUSIONS: The predicted im-
pact of various meningococcal vaccines will likely depend strongly on assumptions
about strain interactions, some of which lead to dynamics that are inconsistent
with observations. While empirical unknowns about strain interactions between
Nm serogroups remain, our results suggest that cross-protection and natural im-
munity assumptions significantly impact predicted multigroup dynamics, and
hence may affect predictions of the health and economic impact of new vaccina-
tion policies.
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OBJECTIVES: Mainstream of psychological researches usually utilizes large sam-
ples, cross-sectional studies and aggregate frames to analyze data and interpret
them. However, the limitations are that the specific features of individuals are not
easy to be revealed and the time effect has been ignored. This study explores both
of the trait-like and state-like properties including global self-esteem, happiness
and the quality of life. By using time series analysis which can examine individual,
longitudinal and non-aggregate data, the properties of psychological measures can
be investigated. METHODS: Ten college students (mean age20.6 year, SD2.18)
and four adults (mean age30.27 year, SD1.23) participated in this study. Each
subject completed six 10-cm visual analogue scale items, once a day for 2 months.
These items measure subject’s global self-esteem, happiness, the quality of life,
positive life events, negative life events as well as random error (i.e., Participant
was asked to make a mark on the center of a line). Time series analysis, including
autoregressive and moving average modeling procedures, was used to examine the
time dependency (i.e., more trait-like) for each item. RESULTS: For the college
sample, 80% of autocorrelation and partial-autocorrelation coefficients were not
significant across time lag. This result doesn’t fully support the existence of time
dependency for each item. On the contrary, 55% of autocorrelation and partial-
autocorrelation coefficients were statistically significance for the adult sample.
Both samples showed significant correlations among psychological measures (self-
esteem, happiness and the quality of life) and life events (positive and negative).
CONCLUSIONS: In conclusion, the results support that self-esteem, happiness and
quality of life may contain both trait-like and state-like properties, and the time
dependency of psychological measures is more stable especially in adults.
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OBJECTIVES: Annual growth prediction models following growth hormone (GH)
treatment have been developed to facilitate treatment guidance. However, accu-
rately predicting height over the long term, during pre-pubertal treatment years
has not been assessed and is a prerequisite for modelling of cost effective optimum
height outcomes. METHODS: Annual prediction models utilised data from large
cohorts sourced from the KIGS database (Pfizer International Growth Database,
comprising 75,000 children with growth disorders) and describe the likely annual
height gain based on patients’ auxological and biochemical characteristics (e.g. GH
dose, age, mid parental height standard deviation [SDS] and weight SDS score) at
treatment start. The most likely long-term height development was simulated
prospectively up to 4 years by sequential application of existing yearly prediction
algorithms for height velocity (HV) and newly developed algorithms for weight gain
A409V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
